Community Bank N.A. Has $2.31 Million Holdings in Bristol-Myers Squibb Co (BMY)

Community Bank N.A. raised its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 6.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 37,693 shares of the biopharmaceutical company’s stock after acquiring an additional 2,247 shares during the period. Community Bank N.A.’s holdings in Bristol-Myers Squibb were worth $2,309,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Hudock Capital Group LLC grew its holdings in shares of Bristol-Myers Squibb by 0.4% during the second quarter. Hudock Capital Group LLC now owns 11,775 shares of the biopharmaceutical company’s stock worth $656,000 after purchasing an additional 49 shares during the last quarter. NTV Asset Management LLC grew its holdings in shares of Bristol-Myers Squibb by 2.2% during the second quarter. NTV Asset Management LLC now owns 36,817 shares of the biopharmaceutical company’s stock worth $2,051,000 after purchasing an additional 800 shares during the last quarter. River & Mercantile Asset Management LLP bought a new stake in shares of Bristol-Myers Squibb during the second quarter worth $869,000. Cambridge Investment Research Advisors Inc. grew its holdings in shares of Bristol-Myers Squibb by 4.4% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 175,400 shares of the biopharmaceutical company’s stock worth $9,773,000 after purchasing an additional 7,404 shares during the last quarter. Finally, Brighton Jones LLC grew its holdings in shares of Bristol-Myers Squibb by 18.7% during the second quarter. Brighton Jones LLC now owns 16,134 shares of the biopharmaceutical company’s stock worth $899,000 after purchasing an additional 2,538 shares during the last quarter. Hedge funds and other institutional investors own 71.55% of the company’s stock.

How to Become a New Pot Stock Millionaire

In other news, Director Theodore R. Samuels II bought 4,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The shares were acquired at an average price of $62.30 per share, with a total value of $249,200.00. Following the transaction, the director now owns 22,000 shares in the company, valued at $1,370,600. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.23% of the stock is currently owned by company insiders.

Several research firms recently issued reports on BMY. TheStreet cut Bristol-Myers Squibb from a “b” rating to a “c+” rating in a report on Thursday, March 8th. ValuEngine cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Wednesday, March 7th. Bank of America raised their price target on Bristol-Myers Squibb from $64.00 to $68.00 and gave the company a “neutral” rating in a report on Monday, March 5th. DZ Bank cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Wednesday, February 28th. Finally, Jefferies Group set a $72.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday, February 26th. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the company’s stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average target price of $66.30.

Bristol-Myers Squibb Co (NYSE BMY) opened at $66.68 on Wednesday. Bristol-Myers Squibb Co has a one year low of $51.56 and a one year high of $70.05. The company has a quick ratio of 1.43, a current ratio of 1.55 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $110,117.72, a PE ratio of 113.02, a price-to-earnings-growth ratio of 2.07 and a beta of 0.98.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The company had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.35 billion. During the same quarter last year, the firm posted $0.63 earnings per share. Bristol-Myers Squibb’s revenue was up 3.9% compared to the same quarter last year. equities research analysts expect that Bristol-Myers Squibb Co will post 3.2 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, May 1st. Investors of record on Friday, April 6th will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 2.40%. The ex-dividend date of this dividend is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio is presently 271.19%.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.themarketsdaily.com/2018/03/14/community-bank-n-a-has-2-31-million-holdings-in-bristol-myers-squibb-co-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply